Z. Berger
13 Papers
Z. Berger is an academic researcher. The author has contributed to research in topics: Medicine & SMA*. The author has an hindex of 2, co-authored 12 publications.
Chat about Author
Papers
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study
Thomas O. Crawford,Kathryn J. Swoboda,Darryl C. De Vivo,Enrico Bertini,Wuh-Liang Hwu,Richard S. Finkel,Janbernd Kirschner,Nancy L. Kuntz,A. Nazario,Julie A. Parsons,Astrid Pechmann,Monique M. Ryan,Russell J. Butterfield,Haluk Topaloglu,Tawfeg Ben-Omran,Valeria A. Sansone,Yuh-Jyh Jong,Francy Shu,Angela D. Paradis,Richard Foster,Z. Berger +20 more
TL;DR: NURTURE (NCT02386553) as discussed by the authors is an open-label study of nusinersen in children with spinal muscular atrophy (SMA) who initiated treatment in the presymptomatic stage.
50
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
Alessio Paris,Pranami Bora,Silvia Parolo,D. MacCannell,Michael Monine,Nick van der Munnik,Xiao Tong,Satish Eraly,Z. Berger,D. Graham,Toby A. Ferguson,Enrico Domenici,Ivan Nestorov,Luca Marchetti +13 more
TL;DR: In this paper , a quantitative system pharmacology model representing the SMA pediatric scenario in the age range of 0-20 years with and without treatment with the antisense oligonucleotide nusinersen was introduced.
7
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
D. MacCannell,Z. Berger,Janbernd Kirschner,Eugenio Mercuri,Michelle A. Farrar,Susan T. Iannaccone,Nancy L. Kuntz,Richard S. Finkel,Marta Valente,Francesco Muntoni +9 more
TL;DR: In this article , the authors describe dosing regimens that allow for the most rapid restoration of steady-state concentrations of nusinersen in the cerebrospinal fluid (CSF) following a treatment interruption during maintenance dosing.
VP.51 Impact of nusinersen on caregiver experience and health-related quality of life (HRQoL) when initiated in the presymptomatic stage of SMA in NURTURE
J. Kirschner,TO Crawford,M. Ryan,Robert Finkel,Kathryn J. Swoboda,Darryl C. De Vivo,Enrico Bertini,HG Hwu,Valeria A. Sansone,Astrid Pechmann,Juan Montes,D. Krasinski,R. Chin,Z. Berger,C. Zhu,Sylvie Raynaud,A. Paradis,N.B. Johnson +17 more
2
P.100 Rationale/design of the phase 3b ASCEND study of investigational higher dose nusinersen in participants with SMA previously treated with risdiplam
B. Darras,Tim Hagenacker,R. Finkel,Eduardo de Oliveira Mercuri,Juan Montes,N. Kuntz,Michelle A. Farrar,Valeria A. Sansone,Z. Berger,D. MacCannell,Cun Shen,Angela D. Paradis,Janice Bohn,J. Wagner,Kathleen C. Somera-Molina +14 more
1